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were positively correlated to age (p  0.05). This effect
was caused by slightly rising total treatment costs over
age and a declining number of patients fulfilling the effec-
tiveness criterion.
CONCLUSION: Cost-effectiveness ratios are positively
correlated to age in the treatment of moderate asthmatics.
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OBJECTIVE: To investigate the feasibility of different
methodologies for a prospective matched-pair design study
on the incremental daily cost of disease for patients with
nosocomial pneumonia (NP) from a hospital’s perspective. 
METHOD: Adult patients newly admitted to three ICUs
with 3 days of hospitalization and without preexisting
pneumonia were followed up daily until discharge (maxi-
mum 30 days). Any new onset of NP was registered. Gen-
der, age, diagnosis at admission, underlying disease, surgery,
ward, further diagnosis, Apache II-Score, and Kropec-
Pneumonia-Risc-Score were preselected as matching cri-
teria for controls. Consumed resources were documented
daily. Costs were calculated by two methods: a combined
bottom-up approach (resource consumption of drugs,
blood products, diagnostics, other medical materials) and
top-down approach (proportionate cost based on ac-
counting figures by ward for all other costs). Alterna-
tively, all costs were calculated top-down based on ad-
ministrative data.
RESULTS: In 25 days 112 patients were registered; 50
met all study criteria, of whom 3 developed nosocomial
pneumonia. Matching was possible only on gender, age,
reason for admission (eight categories), ward, hospital
days until onset, immunosuppressive and respiratory sta-
tus. The average incremental daily cost for patients with
NP was DM 440  140%. Both costing methods led to
similar results (2% difference). The first method required
significantly more time for data collection. The sample
size for a study, given that the 95% confidence range of
cost equals the mean of the incremental cost (33%), is 40
patients with NP, plus an adequate number of controls.
CONCLUSION: The approach involving some bottom-
up data is not feasible for a full study. The top-down only
approach more efficiently leads to quite similar results.
For reconfirmation, a larger sample size would be neces-
sary. However, time saved accompanies a loss in preci-
sion. In the future, more wards, with preferably long av-
erage stays, should be included to efficiently document
more cases of nosocomial pneumonia.
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Smoking is a high-risk behavior affecting the health and
economic welfare of a society. Thus it is important to
quantify the economic burden of the negative impact due
to smoking in Germany. Approximately 33.4% of the
male and 20.4% of the female German population are
current smokers.
OBJECTIVE: This study investigates the healthcare costs
of smoking on the six most frequent diseases associated
with the inhalation of tobacco smoke: lung cancer (ICD
162; attributable to smoking, 89%), cancer of the mouth
and larynx (ICD 140–149, 161; 85%), chronic obstruc-
tive pulmonary disease (COPD, ICD 490–491; 73%),
coronary artery disease (ICD 410–414; 35%), stroke
(ICD 434–438; 28%), and atherosclerotic occlusive dis-
ease (ICD 440; 28%).
METHODS: A data search was carried out using several
literature databases including MedLine and DIMDI, as
well as health insurance and Federal Institute of Statistics
databases.
RESULTS: Total smoking-related costs for these diseases
in Germany are 31.4  109 DM, equivalent to 49% of the
overall costs. In detail (1995 figures), smoking-related lung
cancer contributes 4.8  109 DM, cancer of the mouth and
larynx 2.5  109 DM, COPD 11.3  109 DM, coronary
artery disease 8.6  109 DM, stroke 3.1  109 DM, and
atherosclerotic occlusive disease 1.1  109 DM.
CONCLUSION: The conservative calculation of the eco-
nomic impact based on only 6 of more than 25 diseases
known to be associated with smoking results already in a
burden of more than 31 billion DM. Further detailed
analyses are needed to better quantify the health eco-
nomic impact.
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OBJECTIVES: To calculate the costs and cost-effective-
ness of a fixed combination of diclofenac 75 mg 
 miso-
prostol 200 g bid compared with diclofenac 75 mg bid
in preventing gastropathy in Belgium.
METHODS: We developed a new decision-analytical
model comparing diclofenac 
 misoprostol (DM) to di-
clofenac (D), taking into account clinical data on gastrop-
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athy and data on medical practice in case of gastropathy.
The time horizon was 3 months. Dyspepsia rates, ulcer
rates in patients with symptoms, and silent ulcer rates
were obtained from a large prospective trial (n  514)
and recalculated by using Bayesian analysis. Current
medical management of NSAID-related gastropathy was
obtained through a review of 102 patient records in pri-
mary care and through expert interviews (2 rounds Del-
phi method). Costs were taken from the perspective of
the health insurance. Unit costs were obtained from offi-
cial listings; hospitalization costs for peptic ulcer were
collected from a database of 58 hospitals. 
RESULTS: Effectiveness—expressed as number of pa-
tients free of symptomatic ulcer and as saved lives—was
greater for DM: 4 patients out of 100 developed symp-
tomatic ulcer, compared to 12 with D. In 100,000 pa-
tients, there would be 42 fatal cases with DM, compared
to 106 with D. At a daily cost of 45.57 BEF for DM and
33.46 for D, the results showed an average cost savings
of 2,834 BEF per patient if treated with DM, mainly be-
cause of a reduced hospitalization cost. Sensitivity analy-
sis around the confidence intervals of the key variables
did not change the conclusions. 
CONCLUSIONS: Diclofenac 
 misoprostol is a domi-
nating strategy compared to diclofenac alone. It prevents
gastropathy and is cost-saving for patients needing me-
dium- to long-term treatment with NSAIDs (3 months).
PIM2
COST OF ILLNESS IN EARLY RHEUMATOID 
ARTHRITIS STRATIFIED FOR SOCIAL STATUS
Merkesdal S, Ruof J, Mau W, Zeidler H
Department of Rheumatology, Medical School of Hannover, 
Hannover, Germany
OBJECTIVE: To assess the relationship between differ-
ent components of cost of illness and social status in an
early rheumatoid arthritis (RA) cohort.
METHODS: 133 consecutive outpatients (age: 47  10
years, 63% female) with early RA (mean disease duration:
7  4 months) fulfilling the diagnostic criteria for RA were
enrolled. All patients were gainfully employed at onset of
symptoms (T1). Data collection was performed using stan-
dardized interviews at T1 and 12 months later (T2). The
mean observation period was 19  4 months. Three major
cost components were analyzed: 1) costs for application
and monitoring of disease modifying antirheumatic drugs
(DMARD; direct costs), 2) loss of productivity due to sick
leave, work disability, and other work loss (indirect costs),
and 3) patient-related non-reimbursed costs. Social status
was measured by the patient education level (low or no de-
gree vs higher degrees).
RESULTS: The main results are shown in the table. Indi-
rect costs are significantly higher in patients with lower
levels of education and expenses concerning non-reim-
bursed treatment and medication tend to be less. No dif-
ferences can be seen in the use of DMARD.
CONCLUSION: Indirect costs were found to be especially
related to social strata in patients with early RA. Further
research is needed to identify indicators that may explain
these findings. Distinct therapeutic measures must be taken
for these patients already in early stages of the disease.
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OBJECTIVES: Quality of life (QoL) and related mea-
sures are increasingly used in the evaluation of patients
with arthritis. But a relatively uninvestigated area is the
relationship between QoL, healthcare resource utilization
and costs. We studied the ability of QoL measures to pre-
dict future healthcare resource use.
METHODS: 412 patients with osteoarthritis of the knee or
hip and 796 patients with rheumatoid arthritis completed
QoL assessments. Their healthcare resource use was mea-
sured 6 months later. QoL assessments included SF-36
physical and mental component scores (PCS, MCS), health
assessment questionnaire (HAQ), feeling thermometer (FT),
pain, fatigue (FAT), anxiety (ANX), satisfaction with health
(SAT), and comorbidity (COM). Healthcare resource use
included visits to all healthcare workers, GP/internal medi-
cine visits, hospitalizations, NSAID usage, and gastrointesti-
nal (GI) drug use.
RESULTS: In general, after controlling for the effect of
demographic variables, the best predictors for physician
visits were QoL mental components, global health mea-
sures, and patient global assessment of health. Comorbid-
ity was the best predictor for hospitalization. Use of
Major cost components dichotomized by education level
Education level DMARDcosts
Indirect
costs
Patient-related
costs
Low degree (n  72) 115 552 DM 40 095 DM 690 DM
High degree (n  61) 90 627 DM 22 935 DM 1252 DM
Student’s t-test p  0.1 p  0.005 p  0.1
PCS MCS HAQ FT ANX FAT GIS Pain SAT COM Global
HCV 4.70 7.28 7.12 4.83 5.40 6.35 3.28 5.38 8.75 4.78 6.58
GIV 5.59 7.36 5.61 6.44 5.16 6.12 5.50 5.98 7.39 6.89 6.82
HOSP 1.14 3.85 1.42 2.24 3.09 3.45 2.69 2.07 2.54 4.39 4.81
NSAID 2.59 0.29 2.63 2.34 0.60 2.06 1.78 1.67 2.07 0.24 1.10
GI 1.51 4.69 1.99 4.45 4.23 3.97 8.96 3.63 2.09 6.87 3.12
Z-scores: 1.96  p  0.05; 2.58  p: 0.01; 3.28  p  0.01.
